See the DrugPatentWatch profile for Kadian
What is Kadian and its generic version?
Kadian is the brand name for morphine sulfate extended‑release tablets, used to manage moderate‑to‑severe pain that requires continuous, around‑the‑clock dosing. The generic counterpart contains the same active ingredient—morphine sulfate—but is sold under the generic name “morphine sulfate extended‑release” or simply “Morphine ER” [1][2].
When did the FDA approve the generic?
The first generic morphine ER tablet received FDA approval in 2019, after the original Kadian patent expired. The approval marked the first entry of a generic for this drug into the U.S. market [1].
How does the generic compare to the brand‑name Kadian?
Both products contain the same 30‑mg, 40‑mg, 60‑mg, 80‑mg, or 100‑mg tablet strengths and have identical release mechanisms. Clinical studies used to support the generic’s approval demonstrated bioequivalence to Kadian, meaning the generic releases morphine into the bloodstream at the same rate and extent as the brand. Therefore, patients and prescribers can expect equivalent pain relief and safety profiles [3].
Is the generic safe and effective?
Yes. Because the FDA requires bioequivalence and identical excipient composition for generics, the generic Kadian is considered as safe and effective as the brand. Reported side effects mirror those of the brand, including constipation, nausea, dizziness, and, in higher doses, respiratory depression. No new safety signals have emerged since its approval [2].
Where can I obtain the generic version?
The generic morphine ER is available at most pharmacy chains and online prescription services that stock controlled‑release opioids. Many insurers list the generic as a preferred option, often requiring prior authorization. Patients should discuss availability with their prescriber or pharmacy.
Who makes the generic?
Multiple manufacturers supply the generic: Teva Pharmaceutical Industries, Mylan (now part of Viatris), and Sandoz, among others. Each company offers the same tablet strengths and dosage forms approved by the FDA [4].
How much cheaper is the generic?
Generic morphine ER typically costs between 30 % and 70 % less than brand‑name Kadian, depending on pharmacy pricing and insurance coverage. This price gap can be significant for long‑term pain management plans [2].
Are there patent or exclusivity concerns?
The original Kadian patent expired in 2019, prompting generic entry. No current patents protect the formulation; however, each manufacturer may hold separate patents for specific manufacturing processes or excipients that could influence market dynamics. No major litigation is publicly known as of the latest reports [1][4].
Can I switch from Kadian to the generic safely?
Switching is generally safe, provided the dosage and schedule remain unchanged. Because the generic is bioequivalent, a direct 1:1 switch does not alter efficacy or safety. Patients should monitor for any unusual symptoms and report them promptly. Physicians often prescribe a tapering plan when switching to ensure tolerance and compliance [3].
What side effects should patients be vigilant about?
Both the brand and generic share common opioid side‑effects: constipation, nausea, sedation, and, at high doses, respiratory depression. Patients should adhere to dosing instructions, avoid alcohol, and use prescribed laxatives to mitigate constipation. Any signs of excessive sedation or breathing trouble warrant immediate medical attention.